Liang Zhu1, Wen-Ming Wu2, Hua-Dan Xue3, Wei Liu1, Xuan Wang1, Hao Sun1, Ping Li1, Yu-Pei Zhao2, Zheng-Yu Jin1. 1. Department of Radiology, Peking Union Medical College Hospital, Shuaifuyuan No.1, Dongcheng District, Beijing, China. 2. Department of General Surgery, Peking Union Medical College Hospital, Shuaifuyuan No.1, Dongcheng District, Beijing, China. 3. Department of Radiology, Peking Union Medical College Hospital, Shuaifuyuan No.1, Dongcheng District, Beijing, China. bjdanna95@hotmail.com.
Abstract
OBJECTIVES: To assess enhancement patterns of sporadic insulinomas on volume perfusion CT (VPCT), and to identify timing of optimal tumour-parenchyma contrast. METHODS: Consecutive patients who underwent VPCT for clinically suspected insulinomas were retrospectively identified. Patients with insulinomas confirmed by surgery were included, and patients with familial syndromes were excluded. Two radiologists evaluated VPCT images in consensus. Tumour-parenchyma contrast at each time point was measured, and timing of optimal contrast was determined. Time duration of hyperenhancement (tumour-parenchyma contrast >20 Hounsfield units, HU) was recorded. Perfusion parameters were evaluated. RESULTS: Three dynamic enhancement patterns were observed in 63 tumours: persistent hyperenhancement (hyperenhancement time window ≥10 s) in 39 (61.9%), transient hyperenhancement (hyperenhancement <10 s) in 19 (30.2%) and non-hyperenhancement in 5 (7.9%). Timing of optimal contrast was 9 s after abdominal aorta threshold (AAT) of 200 HU, with tumour-parenchyma contrast of 77.6 ± 57.2 HU. At 9 s after AAT, 14 (22.2%) tumours were non-hyperenhancing, nine of which had missed transient hyperenhancement. Insulinomas with transient and persistent hyperenhancement patterns had significantly increased perfusion. CONCLUSIONS: Insulinomas have variable enhancement patterns. Tumour-parenchyma contrast is time-dependent. Optimal timing of enhancement is 9 s after AAT. VPCT enables tumour detection even if the hyperenhancement is transient. KEY POINTS: • Enhancement patterns of insulinomas are variable and tumour-parenchyma contrast is time-dependent. • An optimized single-phase scan found 77.8% tumours to be hyperenhancing. • Hyperenhancing tumours increase to 84.1% and 87.3% with biphasic/triphasic scan. • Volume perfusion CT enables detection of insulinomas with missed transient hyperenhancement.
OBJECTIVES: To assess enhancement patterns of sporadic insulinomas on volume perfusion CT (VPCT), and to identify timing of optimal tumour-parenchyma contrast. METHODS: Consecutive patients who underwent VPCT for clinically suspected insulinomas were retrospectively identified. Patients with insulinomas confirmed by surgery were included, and patients with familial syndromes were excluded. Two radiologists evaluated VPCT images in consensus. Tumour-parenchyma contrast at each time point was measured, and timing of optimal contrast was determined. Time duration of hyperenhancement (tumour-parenchyma contrast >20 Hounsfield units, HU) was recorded. Perfusion parameters were evaluated. RESULTS: Three dynamic enhancement patterns were observed in 63 tumours: persistent hyperenhancement (hyperenhancement time window ≥10 s) in 39 (61.9%), transient hyperenhancement (hyperenhancement <10 s) in 19 (30.2%) and non-hyperenhancement in 5 (7.9%). Timing of optimal contrast was 9 s after abdominal aorta threshold (AAT) of 200 HU, with tumour-parenchyma contrast of 77.6 ± 57.2 HU. At 9 s after AAT, 14 (22.2%) tumours were non-hyperenhancing, nine of which had missed transient hyperenhancement. Insulinomas with transient and persistent hyperenhancement patterns had significantly increased perfusion. CONCLUSIONS:Insulinomas have variable enhancement patterns. Tumour-parenchyma contrast is time-dependent. Optimal timing of enhancement is 9 s after AAT. VPCT enables tumour detection even if the hyperenhancement is transient. KEY POINTS: • Enhancement patterns of insulinomas are variable and tumour-parenchyma contrast is time-dependent. • An optimized single-phase scan found 77.8% tumours to be hyperenhancing. • Hyperenhancing tumours increase to 84.1% and 87.3% with biphasic/triphasic scan. • Volume perfusion CT enables detection of insulinomas with missed transient hyperenhancement.
Authors: T Ichikawa; M S Peterson; M P Federle; R L Baron; H Haradome; Y Kawamori; S Nawano; T Araki Journal: Radiology Date: 2000-07 Impact factor: 11.105
Authors: R Graziani; A Brandalise; M Bellotti; R Manfredi; A Contro; M Falconi; L Boninsegna; R Pozzi Mucelli Journal: Radiol Med Date: 2010-03-09 Impact factor: 3.469
Authors: Joel G Fletcher; Maurits J Wiersema; Michael A Farrell; Jeff L Fidler; Lawrence J Burgart; Takashi Koyama; C Daniel Johnson; David H Stephens; Ellen M Ward; W Scott Harmsen Journal: Radiology Date: 2003-10 Impact factor: 11.105
Authors: J L Fidler; J G Fletcher; C C Reading; J C Andrews; G B Thompson; C S Grant; F J Service Journal: AJR Am J Roentgenol Date: 2003-09 Impact factor: 3.959
Authors: Wolfgang M Thaiss; Ulrike Haberland; Sascha Kaufmann; Daniel Spira; Christoph Thomas; Konstantin Nikolaou; Marius Horger; Alexander W Sauter Journal: Eur Radiol Date: 2015-12-17 Impact factor: 5.315
Authors: S Gusmini; R Nicoletti; C Martinenghi; C Caborni; G Balzano; A Zerbi; S I Rocchetti; P G Arcidiacono; L Albarello; F De Cobelli; V Di Carlo; A Del Maschio Journal: Radiol Med Date: 2007-10-21 Impact factor: 6.313